Table 2.
Meta-analysis of the association between Fas/FasL polymorphisms and susceptibility to leukemia
| Study groups | OR (95% CI), I2 (%) | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Recessive model | Homozygous model | Dominant model | Allele model | |||||
| Fas-670A/G | GG vs AG/AA | GG vs AA | GG/AG vs AA | G vs A | ||||
| Overall (6) | 0.94 (0.80, 1.09) | 0.0 | 0.93 (0.78, 1.11) | 28.7 | 1.01 (0.89, 1.14) | 47.4 | 0.96 (0.89, 1.05) | 38.6 |
| Caucasian (2) | 1.01 (0.78, 1.30) | 0.0 | 1.10 (0.82, 1.48) | 27.5 | 1.15 (0.92, 1.43) | 20.9 | 1.06 (0.92, 1.23) | 37.4 |
| Asian (3) | 0.90 (0.74, 1.09) | 0.0 | 0.88 (0.71, 1.10) | 0.0 | 0.92 (0.78, 1.07) | 13.4 | 0.93 (0.84, 1.04) | 0.0 |
| AML (2) | 0.93 (0.77, 1.12) | 0.0 | 0.98 (0.79, 1.22) | 0.0 | 1.06 (0.90, 1.25) | 0.0 | 1.00 (0.90, 1.11) | 0.0 |
| ALL (3) | 1.06 (0.75, 1.51) | 0.0 | 1.12 (0.58, 2.17) | 55.2 | 1.05 (0.57, 1.93) | 77.4 | 1.05 (0.72, 1.53) | 71.9 |
| Fas-1377G/A | AA vs GA/GG | AA vs GG | AA/GA vs GG | A vs G | ||||
| Overall (6) | 0.91 (0.74, 1.12) | 13.8 | 0.89 (0.71, 1.12) | 48.2 | 1.06 (0.77, 1.45) | 81.8 | 1.21 (0.82, 1.81) | 94.4 |
| Caucasian (3) | 0.99 (0.76, 1.27) | 42.4 | 1.10 (0.62, 1.96) | 55.0 | 1.20 (0.79, 1.80) | 80.3 | 1.41 (0.82, 2.42) | 95.3% |
| Asian (3) | 0.78 (0.54, 1.11) | 0.0 | 0.69 (0.47, 1.00) | 0.0 | 0.89 (0.57, 1.37) | 75.7 | 0.89 (0.66, 1.22) | 69.1 |
| AML (3) | 1.15 (0.66, 2.03) | 61.0 | 1.26 (0.64, 2.48) | 70.3 | 1.31 (0.80, 2.14) | 88.7 | 1.64 (0.88, 3.04) | 96.7 |
| ALL (2) | 0.75 (0.51, 1.09) | 0.0 | 0.64 (0.43, 0.96) | 0.0 | 0.74 (0.58, 0.95) | 0.0 | 0.78 (0.64, 0.94) | 0.0 |
| FasL-844T/C | CC vs TC/TT | CC vs TT | CC/TC vs TT | C vs T | ||||
| Overall (2) | 0.86 (0.72, 1.03) | 0.0 | 0.60 (0.25, 1.45) | 90.6 | 0.54 (0.17, 1.75) | 96.0 | 0.69 (0.38, 1.25) | 95.3 |
The results that are in bold type show statistical significance. OR, odds ratio; CI, confidence interval.